Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL4901 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1972366 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16651410 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652202 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395674 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL20531399 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709600-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE | Aventis Pharmaceuticals Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20140073670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE | AVENTIS PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2605015-A1 | Kits for determining the interaction of a test compound with two associated receptors | Dimerix Bioscience Pty.Ltd. (AU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2080012-B1 | Methods for assaying test compounds on associated receptors | DIMERIX BIOSCIENCE PTY LTD (AU) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065253-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2013-03-14 | — | — | US | disclosed |
| WO-2012159960-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FEXOFENADINE | AVENTIS PHARMACEUTICALS INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-8283127-B2 | Detection system and uses therefor | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2012-10-09 | — | — | US | disclosed |
| US-20100021457-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20080279768-A1 | Bifunctional Metal Chelating Conjugates | MALLINCKRODT LLC | 2008-11-13 | — | — | US | disclosed |
| WO-2003101476-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279768-A1 | Bifunctional Metal Chelating Conjugates | SLC30A5, SLC39A3, SLC30A6 | HRH1 2870/4885KCNH2 4013/4885LMNA 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.